Introduction
============

The root of *Panax ginseng* C.A. MEYER is frequently used in China as a traditional medicine \[[@B1-molecules-14-02043]\]. Ginsenosides, as the major components of ginseng, have been reported to show various biological activities, *eg.* anti-tumor, anti-inflammatory, immune-modulatory and anti-aging effects \[[@B2-molecules-14-02043],[@B3-molecules-14-02043],[@B4-molecules-14-02043],[@B5-molecules-14-02043]\]. Among the 30 previous reported ginsenosides, Rg~3~, compound K (CK) and Rh~1~ showed highly cytotoxicity against tumor cells \[[@B6-molecules-14-02043],[@B7-molecules-14-02043],[@B8-molecules-14-02043],[@B9-molecules-14-02043]\]. CK was proven to be produced by intestinal microorganisms after oral administration of Rg~3~, and then further esterified to sustain it longer in the body \[[@B10-molecules-14-02043],[@B11-molecules-14-02043]\]. During our continued work on bioactive ginsenosides, an *Aspergillus niger* strain was isolated from the soil around ginseng fruit. *In vitro* enzyme assays showed that this strain had the ability to transform total ginsenosides (TGS) into several new products \[[@B12-molecules-14-02043]\]. In the subsequent biochemical study, a β-glucosidase gene isolated from this strain, *bgl1*, showed the ability to transform ginsenoside Rf to Rh~1~ ([Figure 1](#molecules-14-02043-f001){ref-type="fig"}).

![Scheme of biotransformation from ginsenoside Rf to Rh~1~ catalyzed by BGL1.](molecules-14-02043-g001){#molecules-14-02043-f001}

Results and Discussion
======================

Expression and purification of BGL1 in Saccharomyces cerevisiae
---------------------------------------------------------------

In the present study, the *bgl1* gene isolated from an *Aspergillus niger* strain, which encodes a glucosidase, was cloned into the yeast shuttle vector pRS423 and introduced into *Saccharomyces cerevisiae* (MGY70). SDS-PAGE analysis showed strong expression of a \~170 kDa his-tagged BGL1 protein at 37 ºC ([Figure 2](#molecules-14-02043-f002){ref-type="fig"}, lane 2). The empty pRS423 vector was used as control ([Figure 2](#molecules-14-02043-f002){ref-type="fig"}, lane 3). Soluble recombinant protein purified from cultures grown at 37ºC by his-tagging yielded a single distinct band after SDS-PAGE ([Figure 2](#molecules-14-02043-f002){ref-type="fig"}, lane 4). After dialysis, the purified recombinant BGL1 was quantified at 0.9 µg µL^-1^(total of 5.1 mg from 6 g bacteria cell pellet).

![SDS-PAGE gel of expression and purification of BGL1. Lane 1: Protein marker, 2: Over-expression of BGL1; 3: Empty control; 4: Purified protein.](molecules-14-02043-g002){#molecules-14-02043-f002}

In vitro biotransformation of ginsenoside Rf to Rh~1~
-----------------------------------------------------

Purified BGL1 protein was tested for biotransformation activities with ginsenoside Rf, DM~1~, PM~1~, SM~1~ \[[@B11-molecules-14-02043]\] and compound K. The recombinant protein didn't show any glucosidase activities towards compound K, ginsenosides DM~1~, PM~1~ and SM~1~ but did show the ability to transform ginsenoside Rf into new products, one of which has been identified as ginsenoside Rh~1~ by comparison of the retention time with the authentic compound and further confirmed by LC-MS analysis ([Figure 3](#molecules-14-02043-f003){ref-type="fig"}A and [Figure 3](#molecules-14-02043-f003){ref-type="fig"}B).

![HPLC trace of enzyme assay. A: Trace of substrate ginsenoside Rf; B: Trace of enzyme assay of ginsenoside Rf reacted with BGL1.](molecules-14-02043-g003){#molecules-14-02043-f003}

Conclusions
===========

Ginsenoside Rh~1~ had been reported as a bioactive compound with various pharmacological effects \[[@B6-molecules-14-02043],[@B7-molecules-14-02043],[@B8-molecules-14-02043],[@B9-molecules-14-02043]\], but the amount in the ginseng was relative minor. In the present study, a recombinant *Aspergillus niger* BGL1 protein showed the ability to transform ginsenoside Rf to Rh~1~, increasing the availability of this compound and hence its potential as a drug.

Experimental
============

General
-------

HPLC runs were carried out on a Zorbax C~18~ column (150 x 25 mm, Phenomenex, Torrance, CA, USA) on an Agilent 1100 instrument and UV absorption data (λ~203~) were analyzed with Agilent Chemstation Ver 8.01. All solvents used in this study were HPLC grade, purchased from the Chinese Chemical Group, Beijing, P.R. China. *S. cerevisiae* MGY70 was used as host strain and the yeast shuttle vector pRS423 was used for the construct.

Cloning and Expression of pRS-BGL1 in S. cerevisiae
---------------------------------------------------

Total RNA of overnight cultured *Aspergillus niger* was extracted using an RNAeasy mini kit, (Qiagen, USA). The full-length BGL1 cDNA was cloned using specific primers designed from the mRNA sequence deposited in GeneBank (Accession No. XM.001398779): sense primer 5\'-GC [*CTCGAG*]{.ul} ATGAGGTTCACTTCGATCGA-3\' and antisense primer 5\'- GC [*GAATTC*]{.ul} TTAGTGAACAGTAGGCAGAG-3\', with underlined nucleotides representing restriction sites included for *XhoI* and *EcoRI*. The PCR product was purified by a Mini-PCR purification kit (Invitrogen, USA), ligated into a pRS423 expression vector, sequenced and then introduced into *Saccharomyces cerevisiae*, selecting for growth on yeast nitrogen base (YNB) minimal medium (Difco) lacking histidine as appropriate.

Purification of recombinant BGL1 protein
----------------------------------------

All steps were carried out at 4 ºC. His-tagged BGL1 protein was purified from the soluble fraction using a His-Bind purification kit (Novagen) following the manufacture's protocol. Briefly, cells were freeze-thawed 3 times in binding buffer (500 mM NaCl, 20 mM Tris-HCl and 20 mM imidazole, PH 7.9). The suspension was incubated with lysozyme on ice for 30 min, and sonicated, the supernatant was collected by centrifugation at 14,000 g for 20 min and applied to pre-equilibrated His-Bind resin. Bound resin was washed three times with wash buffer (500 mM NaCl, 20 mM Tris-HCl and 60 mM imidazole, PH 7.9), then his--tagged protein was elute twice with three bed volumes of elution buffer (500 mM NaCl, 20 mM Tris-HCl and 1 M imidazole, PH 7.9), dialyzed three times against 1×PBS (140 mM NaCl, 2.7 mM KCl, 1.4 mM KH~2~PO~4~ and 8 mM Na~2~HPO~4~, PH 7.4) to remove immidazole and examined by SDS-PAGE on 13% denaturing gel.

Enzyme Activity
---------------

To test the potential of BGL1 to catalyze the biotransformation of ginsenosides, *in vitro* enzyme assay conditions were altered to include incubation at 37 ºC for 12 h in 1 mL total volume containing 850 µL Tris-HCl buffer (100 mM, PH 7.0), 50µl purified BGl1 protein (0.9 µg µL^-1^ ), 100 µL ginsenoside (1 µg µL^-1^). Tested ginsenosides included ginsenosides Rf, DM~1~, PM~1~, SM~1~ and compound K. The reaction mixture with ginsenosides was centrifuged and subjected to HPLC for analysis (20 µL injection), at ambient temperature, a linear gradient of 5% to 65% Acetonitrile (containing 0.05% formic acid), (v/v) (flow rate of 1.0 mL/min), and monitored by PDA at A~203~.
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